The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH 2022 | Highlights from BSH: genetic profiling in CLL
Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, shares some highlights from BSH 2022, briefly discussing a presentation which focused on the genetic profiling of chronic lymphocytic leukemia (CLL), and the importance of investigating genomic aberrations in this disease. Dr Eichhorst highlights the complexity of CLL, and the need to further evaluate genomic data to improve and personalize treatment approaches for patients. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
Disclosures
I receive honoraria for presentations and advisory board from several different pharmaceutical companies involved in targeted agents in CLL (Abbvie, BeiGene, BMS, Gilead, Janssen, MSD, Roche).
